Adamis Pharmaceuticals Corp (38)

Browse by Contract Category

Contracts

Registration Rights Agreement, dated July 5, 2022, between Adamis Pharmaceuticals Corporation and the parties thereto (Filed With SEC on July 6, 2022)
Executive Employment Agreement between the Company and David C. Benedicto dated as of June 22, 2022 (Filed With SEC on June 24, 2022)
(Filed With SEC on March 31, 2022)
First Amendment to Exclusive License Agreement dated November 9, 2021 between the Company and Matrix Biomed, Inc (Filed With SEC on March 31, 2022)
Settlement Agreement between the Company, US Compounding Inc., Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., Nephron Sterile Compounding Center, LLC and certain other... (Filed With SEC on November 22, 2021)
Lease Agreement between the Company and Oil States Energy Services, LLC, as amended (Filed With SEC on April 15, 2021)
Securities Purchase Agreement, dated July 5, 2022, between Adamis Pharmaceuticals Corporation and the parties thereto (Filed With SEC on July 6, 2022)
Common Stock Purchase Warrant dated July 5, 2022 (Filed With SEC on July 6, 2022)
Press Release issued May 26, 2022 (Filed With SEC on May 26, 2022)
Separation Agreement and Release dated as of May 18, 2022 (Filed With SEC on May 19, 2022)
Executive Employment Agreement between the Company and David J. Marguglio dated as of May 18, 2022 (Filed With SEC on May 19, 2022)
Press Release dated October 4, 2021 (Filed With SEC on October 4, 2021)
Supply Agreement Addendum by and among the Registrant, US Compounding, Inc. and Fagron Compounding Services, LLC (Filed With SEC on August 5, 2021)
Asset Purchase Agreement effective as of July 30, 2021, by and among the Registrant, US Compounding, Inc. and Fagron Compounding Services, LLC (Filed With SEC on August 5, 2021)
Promissory Note dated March 15, 2021 (Filed With SEC on April 15, 2021)
(Filed With SEC on April 15, 2021)
Description of the Registrant's Capital Stock (Filed With SEC on April 15, 2021)
Underwriting Agreement, dated January 29, 2021, by and between Adamis Pharmaceuticals Corporation and Raymond James & Associates, Inc., as representative of the underwriters named... (Filed With SEC on January 29, 2021)
Underwriting Agreement, dated September 18, 2020, by and between Adamis Pharmaceuticals Corporation and Raymond James & Associates, Inc., as representative of the underwriters... (Filed With SEC on September 18, 2020)
August 2020 Amendment to Loan Amendment and Assumption Agreement between the Company and Arvest Bank (Filed With SEC on September 15, 2020)
Amended Promissory Note between the Company and Arvest Bank (Filed With SEC on September 15, 2020)
2020 Equity Incentive Plan (Filed With SEC on August 24, 2020)
Distribution and Commercialization Agreement between the Company and USWM, LLC (Filed With SEC on August 17, 2020)
*** Certain identified information hasbeen omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrantif publicly... (Filed With SEC on August 17, 2020)
*** Certain identified information hasbeen omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrantif publicly... (Filed With SEC on August 17, 2020)
*** Certain identified information hasbeen omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrantif publicly... (Filed With SEC on August 17, 2020)
Description of the Registrants Common Stock (Filed With SEC on June 22, 2020)
Adamis Pharmaceuticals Corporation 2020 Bonus Plan (Filed With SEC on June 22, 2020)
Promissory Note date April 10, 2020 (Filed With SEC on April 15, 2020)
DESCRIPTION OF CAPITAL STOCK (Filed With SEC on March 30, 2020)
Placement Agency Agreement (Filed With SEC on February 21, 2020)
Form of Securities Purchase Agreement (Filed With SEC on February 21, 2020)
Form of Warrant (Filed With SEC on February 21, 2020)
Form of Warrant dated August 5, 2019 (Filed With SEC on November 12, 2019)
Form of Stock Appreciation Rights Agreement for Non-Employee Directors (Filed With SEC on November 12, 2019)
Underwriting Agreement, dated August 1, 2019, by and between Adamis Pharmaceuticals Corporation and Raymond James & Associates, Inc., as representative of the underwriters named... (Filed With SEC on August 1, 2019)
Form of Warrant (Filed With SEC on August 1, 2019)
Adamis Pharmaceuticals Corporation 2019 Bonus Plan (Filed With SEC on February 5, 2019)